z-logo
open-access-imgOpen Access
In Vivo Detection of Human TRPV6-Rich Tumors with Anti-Cancer Peptides Derived from Soricidin
Author(s) -
Chris V. Bowen,
Drew R. DeBay,
H. Stephen Ewart,
Pamela Gallant,
Sean Gormley,
T. Toney Ilenchuk,
Umar Iqbal,
Tyler Lutes,
Marzia Martina,
Geoffrey Mealing,
Nadine Merkley,
Sandra Sperker,
María Moreno,
Christopher Rice,
Raymond T. Syvitski,
John M. Stewart
Publication year - 2013
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0058866
Subject(s) - in vivo , cancer research , biology , ovarian cancer , prostate cancer , medicine , cancer , microbiology and biotechnology
Soricidin is a 54-amino acid peptide found in the paralytic venom of the northern short-tailed shrew ( Blarina brevicauda ) and has been found to inhibit the transient receptor potential of vallinoid type 6 (TRPV6) calcium channels. We report that two shorter peptides, SOR-C13 and SOR-C27, derived from the C-terminus of soricidin, are high-affinity antagonists of human TRPV6 channels that are up-regulated in a number of cancers. Herein, we report molecular imaging methods that demonstrate the in vivo diagnostic potential of SOR-C13 and SOR-C27 to target tumor sites in mice bearing ovarian or prostate tumors. Our results suggest that these novel peptides may provide an avenue to deliver diagnostic and therapeutic reagents directly to TRPV6-rich tumors and, as such, have potential applications for a range of carcinomas including ovarian, breast, thyroid, prostate and colon, as well as certain leukemia's and lymphomas.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom